Introduction:
Angiogenic factors have been investigated for the treatment of ischemic heart disease for more than a decade. Animal and clinical data indicate that angiogenic factors such as FGF (1) (2) (3) , VEGF(4-6) and angiopoietins (7) can induce angiogenesis in ischemic myocardium and improve cardiac function. However, a potential problem associated with prolonged and high-level expression of angiogenic factors, such as VEGF, is hemangioma formation in the heart (8, 9) and the limb (10) . Hence, it is important to modulate the expression of the angiogenic proteins. For the treatment of ischemic heart disease, an ideal control is for the expression of angiogenic factors to respond to hypoxia. By using 9 copies of HRE isolated from the erythropoietin (Epo) gene enhancer, we showed previously that VEGF gene expression could be regulated to respond to hypoxiainduction in vitro and in vivo (11) . However, with intra-myocardial delivery in the rat, the injected vectors have been found to infect extra-cardiac tissues (12) .
Unwanted angiogenesis may also occur in these tissues even with HRE controlled angiogenic gene expression, as hypoxia may exist in these tissues as well due to vascular diseases, cardiac failure, or occult tumors.
In this study, we first investigated AAV vector distribution after intra-myocardial injection in the mouse and found the vectors in several extra-cardiac organs. We then tested the use of a cardiac-specific promoter combined with the HRE, to mediate both cardiac-specific and hypoxia-inducible gene expression. We chose the MLC-2v promoter because this contractile protein is abundant in slow twitch skeletal and cardiac muscles (13) . Although the MLC-2v promoter is 3kb long, critical elements that mediate cardiac-specific gene expression are located within first 250-bp (14, 15) . We constructed an AAV vector with the 250-bp MLC-2v promoter and 9 copies of Epo HRE driving VEGF gene expression. VEGF expression mediated by this vector was studied in vitro and in vivo. Angiogenesis and functional improvement mediated by this vector in ischemic mouse hearts were also analyzed.
Material and Methods:
AAV vector construction and production A primer set, 5'-GGCCAGATCTTAGACAATGGCAGGACCCAG (sense) and 5'-GGCCAAGCTTGAATTCAAGGAGCCTGCTGG (anti-sense), was used to PCR amplify the 250 bp of rat MLC-2v promoter. This promoter was cloned between 9 copies of Epo HRE and human VEGF 165 cDNA in an AAV vector to generate MLCVEGF (Fig. 1) . CMVVEGF (AAV-VEGF), and CMVLacZ (AAV-LacZ) constructed for previous experiments (11, 16) were used as control (Fig. 1) . AAV serotype 2 vectors were prepared by using the three plasmids co-transfection system (17) .
Measurement of VEGF production by cultured cells infected with VEGF expressing vectors
Rat cardiomyocytes (H9C2) (18) , rat skeletal myocytes (L6) and mouse fibroblasts (NIH3T3) (American Type Culture Collection, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum. H9C2 and L6 cells were cultured in 10% CO 2 and NIH3T3 in 5% CO 2 . Anoxia induction and measurement of VEGF expression were conducted using the previous described methods (11) .
Inoculation of vectors into ischemic heart
Mice were housed in the animal care facility of University of California, San Francisco (UCSF), and experiments were conducted according to guidelines for rodent surgery and a protocol approved by the Institutional Animal Care and Use Committee of UCSF. CD1 mice (male and female) (Charles River, Wilmington, MA) were used. Left anterior descending coronary artery (LAD) ligation and viral vector inoculation were performed as previous described (11, 16) .
PCR and real-time RT-PCR analyses
The TRIzol RNA isolation system (Invitrogen Life Technologies, Philadelphia, PA) was used to isolate RNA and genomic DNA. 2µg of genomic DNA were used for PCR amplification of AAV genomes. Total RNA was DNase treated and purified using RNeasy Mini Kit (Qiagen Inc., Valencia, CA). First-strand DNA was synthesized with SuperScript II reverse transcriptase (Invitrogen Life Technologies). 2µg aliquot of the treated total RNA was used for each sample. 5µl of cDNA from each sample was used for PCR amplification. RNA without RT were also amplified and used as negative control to rule out possible genomic DNA contamination. Mouse hypoxanthine phosphoribosyl transferase (mHPRT) was used as internal control. For real-time PCR, the cDNA was diluted 1:10, and 5 µl was added to each reaction. PCR were performed using Taqman Master Mix and Taqman Real-Time PCR detection system (ABI PRISM 9700HT, Applied Biosystem). The primers sequences and the method used for real-time PCR data analysis are described in the supplement.
Histological and immunohistochemical analyses
Serial frozen sections were made from the apex of the heart to the site of the ligation. Infarct size was reconstructed with serial Trichrome stained sections.
CMVLacZ infected cells were detected by LacZ staining. Anti PECAM-1 (Santa Cruz Biotechnology, Inc., Santa Cruz) and anti smooth muscle α-actin (Sigma, St. Louis, MO) antibodies were used to stain endothelial cells and vascular smooth muscles. Immunohistochemical staining was conducted using the standard protocol of Elite Vectastain ABC Kit (Vector Laboratories, Inc., Burlingame, CA).
Echocardiogram
Transthoracic echocardiogram on conscious mice was performed with an Acuson Sequoia c256 using a 15-MHz linear array transducer (15L8). After the anterior chest was shaved, the mouse was inserted into a plastic cone (Mouse Decapicone, Braintree Scientific Inc., Braintree, MA) in a prone position, to restrain its activity. The cone was fixed with adhesive tapes and warm ultrasound transmission gel (Aquasonic 100) was used to fill the space between the chest and the cone. Care was taken to avoid excessive pressure on the thorax, which can induce bradycardia, and two-dimensional imaging was obtained.
Statistical Analysis
Student's t-tests and ANOVA testing were used to comparing the differences among groups, with statistical significance considered if P≤0.05. The data are presented as mean±SD.
Results:
Detection of AAV genome in multiple extra-cardiac organs after intra-myocardial injection AAV vector distribution in the mouse after intra-myocardial injection of CMVVEGF was analyzed by PCR genomic DNA isolated from the brain, heart, lung, liver, kidney, spleen, gonad and diaphragm 2 weeks (3 mice) and 6 months (2 mice) after the injections. Genomic DNAs isolated from a normal uninjected heart and a HEPES buffer injected heart were used as negative controls. Vectors were detected from all three mouse hearts collected 2 weeks after vector inoculation and 1 of the 2 mouse hearts collected 6 months after vector injection ( These results suggest that the AAV vector had leaked out of the heart at or after intra-myocardial injection.
Enhancement of anoxic response in cultured cardiomyocytes by MLCVEGF To limit the VEGF expression in heart and to achieve hypoxia-inducible gene expression, an AAV vector (MLCVEGF, Fig. 1 ) with 9 copies of Epo HRE and 8 250 bp MLC-2v promoter driving VEGF was constructed. The gene expression mediated by MLCVEGF vector was tested in vitro using H9C2 cells (rat cardiac myocyte), L6 (rat skeletal myocyte) and NIH 3T3 (mouse fibroblast). NIH3T3 have been used in our previous study (11) and expressed LacZ 10 times higher in anoxic condition than normoxic condition after infection with an AAV vector carrying 9 copies Epo HRE and minimum SV40 promoter driving LacZ gene.
CMVVEGF was also used to infect these cell lines as control. The cells were cultured in normoxic and anoxic conditions after the infection. The ratios of VEGF expression between anoxic and normoxic conditions of all the three cell lines were near one after CMVVEGF infection. In contrast, these ratios with MLCVEGF infection were 8.7 for H9C2, 2.9 for L6 and 3.7 for NIH3T3. The ratios of VEGF expression between H9C2 cell and NIH3T3 cell were 1.8 (normoxic condition) and 4.2 (anoxic condition), between H9C2 and L6 were 6.2 (normoxia condition) and 8.7 (anoxic condition) ( (Fig. 3 ). The differences in gene expression between ischemic and normal hearts were significant (p=0.01) with MLCVEGF inoculation.
Heart specific VEGF gene expression mediated by MLCVEGF Genomic DNA analysis showed that liver is the most frequent organ that has detectable viral sequences followed by spleen and diaphragm after intramyocardial injection. We compared VEGF expression in the liver (by real- in the hearts of these groups also had more capillaries and α-actin positive vessels than the anterior walls of the three control groups (CMVLacZ, HEPES and uninjected groups) (Fig. 7b) . In anterior area 1, the differences in capillary to muscle ratios and density of α-actin positive vessels were significant between MLCVEGF group and all three control groups (P<0.01). In anterior area 2, significant differences were seen between MLCVEGF and HEPES for the α-actin positive vessels, and uninjected group for capillary density (P≤0.03). Table 2 ). The differences between the VEGF-injected groups and all three control groups were significant (P≤0.05 for all). Thus, MLCVEGF mediated new blood vessel formation around injection sites and resulted in smaller infarcts in treated mice compared to control mice.
Discussion:
Ischemic heart disease remains the leading cause of morbidity and mortality in the Western world. Current therapeutic approaches aim to relieve symptoms and cardiac events by reducing myocardial oxygen demand with medical therapy, or by restoring blood flow by coronary angioplasty or bypass surgery. However, the ability to accomplish revascularization in some patients with diffuse disease is limited. Therapeutic angiogenesis, using angiogenic growth factors or cytokines to stimulate collateral blood vessel formation is being tested as an alternative treatment (20, 21) .
Gene therapy has the potential advantage of maintaining expression of the angiogenic factors at a sufficient concentration over a long period from a single administration. We have used AAV vector to deliver the VEGF gene into the ischemic myocardium of mice, and were able to induce neo-vasculature formation in ischemic hearts (16 In this study, we used the 250-bp MLC-2v promoter and 9 copies of Epo HRE to drive VEGF gene expression specifically in the heart in response to hypoxia induction. MLC-2v promoter is the best characterized promoter for ventricularspecific gene expression in embryonic and adult hearts(26). Although the MLC2v promoter is 3 kb long, transgenic mouse studies have identified the first 250-bp sequence of the promoter to be adequate for ventricular-specific gene expression in embryonic and adult hearts (13, 27) . The key element for ventricular-specific gene expression is the 28-basepair HF-1 (14, 15, 28) . The endogenous cardiac MLC-2v gene is expressed at high levels in both mouse cardiac and slow twitch skeletal muscles. However, high level of luciferase activity was only detected in cardiac muscle of transgenic mice harboring the 250-base pair rat cardiac MLC-2v promoter driving luciferase. Luciferase was not expressed at detectable levels in slow twitch skeletal muscle of these mice (13) . When inserted into an adenoviral or an AAV vector, this promoter mediated cardiac specific reporter gene expression both in neonatal rat and adult mouse after intravenous and intra-ventricular cavity injection(29-31). In our study, this promoter was used to mediate VEGF expression in the acute ischemic adult mouse heart. We demonstrated that the 250-bp MLC-2v promoter plus 9 copies of Epo HRE increased VEGF expression by 74% in ischemic hearts compared to normal hearts. Since RNA was isolated from whole heart in our study, the hypoxia induction of gene expression may be under estimated. Although MLCVEGF DNA sequence was detected in livers and diaphragms of MLCVEGF injected mice, no VEGF expression was detected. In contract, LacZ expression mediated by co-injected CMVLacZ vector was detected in these organs and VEGF expression was found in the organs of CMVVEGF injected mice that have detectable vector sequences. With cardiac-specific gene expression, the densities of capillaries and small vessels were increased in the myocardium and in the scar around MLCVEGF injection site. Also, the MLCVEGF-injected mice, compare to non-VEGF injected controls, had smaller infarct sizes and better cardiac functions, that were comparable to the CMVVEGF injected group.
In conclusion, both cardiac-specific and hypoxia-inducible VEGF expression were achieved with the 250-bp MLC-2v promoter and 9 copies of Epo HRE. 
